Status:
UNKNOWN
The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
Lead Sponsor:
Shenzhen Fifth People's Hospital
Conditions:
Cancer, Therapy-Related
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To observe the effect of thalidomide combined with megestrol acetate on lymphocyte, inflammatory factor regulation and nutritional status in patients with advanced malignant tumors.
Detailed Description
This study was to select 200 patients with advanced tumors with an estimated survival of ≥ 2 months. 50 patients were randomly assigned to each group. The patients were divided into chemotherapy group...
Eligibility Criteria
Inclusion
- Patients with advanced malignant tumor confirmed by histopathology or cytology (hepatocarcinoma can be clinical diagnosis)
- Must be able to swallow pills
- The age of the tester ≥ 18 years old
- Gender is not limited
- Kamofsky score \> 20 points
- Estimated survival period ≥ 2 months
- Childbearing age Women need negative pregnancy test
- Patients voluntarily sign informed consent and receive follow-up
- The tester can cooperate to observe adverse events and efficacy
- All of the above conditions can be included
Exclusion
- Active upper digestive tract ulcers, obvious vomiting, chronic diarrhea, intestinal obstruction, malabsorption, etc; other patients have been known to affect drug absorption, distribution, metabolism or clearance
- 2 or more important organ dysfunction
- Thrombosis Embolism history, except for thrombosis caused by PICC
- Patients suspected of having a history of allergy to thalidomide tablets
- Any significant clinical and laboratory abnormalities that researchers believe affect safety evaluators, such as: uncontrollable activity Microbial infection, grade II or above peripheral neuropathy (NCI CTC AE v4.0), congestive heart failure, myocardial infarction within 6 months, chronic kidney disease, thyroid dysfunction etc, and acceptance may bring significant metabolic or weight changes Patients with clinical disposition
- Patients with mental disorders, affecting the efficacy of the assessor
- During the trial period and within 3 months after the end of the trial, the subject and his partner are not willing to contraception
- Any of the above can not be enrolled.
Key Trial Info
Start Date :
December 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 10 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03777930
Start Date
December 10 2018
End Date
June 10 2021
Last Update
December 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.